TLR7 Antibody
- Known as:
- TLR7 Antibody
- Catalog number:
- XW-7625
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- TLR7 Antibody
Related genes to: TLR7 Antibody
- Gene:
- TLR7 NIH gene
- Name:
- toll like receptor 7
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- Xp22.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-04-27
- Date modifiied:
- 2016-10-05
Related products to: TLR7 Antibody
Related articles to: TLR7 Antibody
- Hookworm disease is one of the tropical neglected diseases that significantly impacts human health to varying degrees. Hookworms produce various proteins to facilitate host invasion and immune evasion. Despite available treatments, reinfection is common, underscoring the need for effective vaccines. However, the complexity of the hookworm's life cycle poses a challenge in understanding the immune response in the vaccine candidates. Reverse vaccinology (RV) offers a powerful approach to understand the immune response by using various bioinformatics tools. This study begins by identifying hookworm antigens capable of inducing host immune responses, followed by docking analysis with different dendritic cell (DC) receptors to investigate the immunological response of antigenic peptides and further correlated to the immunogenicity findings in clinical trial. Necator americanus GlutathioneS-Transferase-1 (Na-GST-1), a known immunogenic protein from Necator americanus, was selected for docking due to its strong antigenic properties. Fifteen DC receptors were evaluated against Na-GST-1, of which seven receptors (TLR2, TLR3, TLR4, TLR7, DEC-205, CD206, and CD36) exhibited stronger predicted interactions, as indicated by stronger binding affinities with Na-GST-1 utilizing various immunoinformatic tools. These receptors are associated with the mediation of Th1/Th2 immune responses, suggesting a potential correlation between docking affinity and the predicted immunogenicity of Na-GST-1. Overall, this study provides valuable insights into DC receptor-antigen interactions and demonstrate a computational approach for assessing the potential of hookworm antigens to engage DC receptors, thereby supporting rational hookworm vaccine design. These findings support the application of early in silico strategies for advancing vaccine candidates against hookworm infection and strengthening control efforts for neglected tropical diseases. - Source: PubMed
Chong S XLee V SChoong W LSahimin NAbu Bakar SLee H Y - Toll-like receptor 7/8 agonists (TLR7/8a), such as resiquimod (R848), are highly potent in activating dendritic cells and thus hold promise for T cell-mediated tumor immunotherapies. However, the short half-life of these small molecules in the lesion and the associated systemic immunotoxicity post-leakage of the drug into the circulation make their clinical application challenging. - Source: PubMed
Publication date: 2026/05/12
Zhang YueSun XueyiCheng ShixuanQian SiyuWan NaXing FengyunLi HongwenGu HangWang ZeyuanDong MengYang ZhenzhenWu ShaoxuanZhang MingzhiHan ZhiqiangZhang XudongLiu HuitaoChen Qingjiang - Systemic lupus erythematosus (SLE) is a polygenic autoimmune disorder where genetic diversity drives significant clinical heterogeneity. This review summarizes the current understanding of the roles of genetic polymorphisms in immunological dysregulation, organ-specific manifestations and therapeutic response heterogeneity in individuals with SLE. The literature was obtained from PubMed, EBSCOhost, Web of Science and Scopus. The narrative review comprised 60 publications published within the last 12 years. The research consistently identifies the major histocompatibility complex (MHC) region as the most significant genetic risk factor for the onset of autoimmunity. Genetic variants in and exacerbate disease progression by facilitating chronic inflammation. These genetic factors are associated with various clinical outcomes, including renal and neuropsychiatric symptoms. Polymorphisms in HLA class II, and are notably linked to serious consequences, including lupus nephritis (LN). Progress in targeted therapy signifies a transition to personalized medicine with medications such as anifrolumab, litifilimab, iberdomide and Janus kinase (JAK) or Cyclin-Dependent Kinase (CDK) inhibitors, demonstrating potential for targeting pathways associated with the interferon gene signature and polymorphisms. Notwithstanding the problems presented by the heterogeneity of SLE, the identification of risk variations is anticipated to enhance predictive and therapeutic biomarkers, hence facilitating more precise and individualized disease management. - Source: PubMed
Publication date: 2026/04/29
Egan Audrey MatildaJohdi Nor AdzimahAzizan Elena AishaMohd RozitaRajalingham SakthiswaryShaharir Syahrul SazliyanaZailani Mohamed Afiq Hidayat - Immunotherapy has emerged as a new pillar of cancer therapeutics that utilizes the patient's own immune system to target tumor cells, a particular advantage in the context of hard-to-treat cancers. Virus-based immunotherapies have shown great potential as cancer treatments, including oncolytic viruses, viral vectors and virus-like particles. Here, we discuss the development, applications, challenges, and future opportunities of cowpea mosaic virus (CPMV) as a plant virus-based candidate for intratumoral immunotherapy, focusing on the treatment of aggressive, metastatic and refractory solid tumors. Evidence of antitumor efficacy has been gathered from mouse tumor models and veterinary clinical trials involving canine cancer patients. CPMV is promising as a monotherapy and as part of combination therapies, including chemotherapy, radiation, checkpoint inhibitors, and cytokine therapies. The putative mechanism of action is described, highlighting key features such as the capsid proteins and RNA acting as Toll-like receptor (TLR) agonists for TLR-2, TLR-4 and TLR-7, as well as the presentation of unique epitopes that prime a Th-1 balanced immune response. The nanoparticle structure of CPMV enhances efficacy by exerting multivalency and avidity effects. The biodistribution, toxicity, and agronomical safety profile of CPMV is also described, especially in relation to tumor retention, hematologic toxicity, allergenicity and adverse events, and viral shedding. This body of work provides a thorough exploration of a novel cancer immunotherapy in development for more than 10 years, positioning CPMV as a versatile intratumoral platform with promise for hard-to-treat cancers. - Source: PubMed
Publication date: 2026/05/11
Pottenger Ayumi EOmole Anthony OSteinmetz Nicole F - A large body of evidence indicates that Th17 cells play essential roles in mucosal immune responses and trigger autoimmune diseases, including multiple sclerosis, inflammatory bowel disease, and psoriasis. Targeting Th17 cells holds promise for therapeutic innovation. While the core cytokine signaling networks driving Th17 differentiation have been extensively characterized, the roles of non-canonical secreted factors in Th17 polarization and pathogenicity remain incompletely understood. Here, we found that Serpine1 was preferentially induced in Th17 cells. Genetic ablation of Serpine1 inhibited Th17 cell polarization in vitro, reproducing the phenotype observed with pharmaceutical inhibition of PAI-1, the product of Serpine1. Furthermore, in a TLR7/8-driven inflammatory skin model induced by imiquimod (IMQ), deletion or inhibition of Serpine1 significantly attenuated disease severity and reduced skin inflammation. Notably, this protective effect was also recapitulated in T cell-specific Serpine1 conditional knockout mice, confirming a T cell-intrinsic role for Serpine1 and ruling out non-T-cell-autonomous effects. Collectively, our results revealed a critical and T cell-intrinsic role for Serpine1 in Th17 differentiation and autoimmune pathology, suggesting that Serpine1/PAI-1 may contribute to Th17-mediated inflammation. - Source: PubMed
Saimaier KaidireyaXie LingWang ChunLv JieLiu GuangyuHan SanxingLi ChunliangDu Changsheng